Skip to main
IVVD
IVVD logo

Invivyd Inc (IVVD) Stock Forecast & Price Target

Invivyd Inc (IVVD) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Invivyd Inc has recently bolstered its financial foundation by closing a $57.5 million public offering, which will support its ongoing clinical programs and extend its financing runway. The company's Phase 1/2 ‘extreme-dose’ trials have demonstrated strong safety profiles, instilling high confidence in the long-term use of its antibody candidates, ADG20 and VYD222. With the upcoming REVOLUTION launch dictating a positive regulatory and commercial narrative, Invivyd is positioned favorably in the market, preparing for pivotal trials that could enhance its competitive edge in addressing viral diseases.

Bears say

The negative outlook on Invivyd Inc.'s stock is primarily driven by a revision of market expectations for its product PEMGARDA, particularly concerning its potential share in the immunocompromised patient sector, resulting in a significant price target reduction. Additionally, dilution from recent capital raises has further weakened the company’s financial position, raising concerns about its ability to compete effectively in the antibody-based treatment space. While Invivyd aims to address limitations in current vaccines through engineered immunity, the challenges of achieving meaningful market penetration amid existing vaccine reluctance and competition still loom large, threatening the company's revenue prospects.

Invivyd Inc (IVVD) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Invivyd Inc (IVVD) Forecast

Analysts have given Invivyd Inc (IVVD) a Buy based on their latest research and market trends.

According to 4 analysts, Invivyd Inc (IVVD) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.39, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.39, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Invivyd Inc (IVVD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.